Papers/PMID:36417631
Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
Revista da Associacao Medica Brasileira (1992)2022The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
cannabidiol — increases serious adverse event incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“This analysis demonstrated an increased risk of serious AEs with the use of CBD when compared to placebo [RD=0.16 (95%CI 0.07–0.26; I2=72%)], NNT=6.”
Quoted verbatim from Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.. - Study
- meta-analysis
- Dose
- 5 to 50 mg/kg/day in two divided doses
- Population
- Children and adults with Dravet syndrome, Lennox-Gastaut syndrome or tuberous sclerosis complex; CBD plus usual antiseizure therapy versus placebo plus usual therapy
Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.2022PMID:36417631Permalink